<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000637713"><TermName>SC-PEG E. coli L-asparaginase</TermName><TermPronunciation>(… as-PAYR-uh-jih-NAYS)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat acute lymphoblastic leukemia (ALL). It is a form of the anticancer drug PEG-asparaginase that stays in the body longer. SC-PEG E. coli L-asparaginase is an enzyme that breaks down the amino acid asparagine and may block the growth of tumor cells that need asparagine to grow. It is a type of protein synthesis inhibitor. Also called EZN-2285 and Oncaspar-IV.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000722807" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;SC-PEG E. coli L-asparaginase&quot;" language="en" id="_3"/><MediaLink ref="CDR0000722808" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;SC-PEG E. coli L-asparaginasa&quot;" language="es" id="_4"/><SpanishTermName>SC-PEG E. coli L-asparaginasa</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para tratar la leucemia linfoblástica aguda (LLA). Es una forma del medicamento PEG-asparaginasa que permanece por más tiempo en el cuerpo. SC-PEG E. coli L-asparaginasa es una enzima que descompone el aminoácido asparagina y puede bloquear el crecimiento de las células tumorales que necesitan asparagina para crecer.   Es un tipo de inhibidor de la síntesis de proteínas. También se llama EZN-2285 y Oncaspar-IV.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2009-03-13</DateFirstPublished></GlossaryTerm>
